Nobel Signs Licensing Deal With SRI For Endometriosis Drug
This article was originally published in PharmAsia News
Executive Summary
Nobel Pharma Japan has entered into a license agreement with SRI International regarding the domestic clinical trials and development of SRI’s endometriosis drug candidate SR16234.